The stock of Kindred Biosciences Inc (NASDAQ:KIN) is a huge mover today! About 140,699 shares traded hands or 322.68% up from the average. Kindred Biosciences Inc (NASDAQ:KIN) has risen 30.63% since February 29, 2016 and is uptrending. It has outperformed by 18.41% the S&P500.
The move comes after 8 months positive chart setup for the $109.14M company. It was reported on Oct, 3 by Barchart.com. We have $7.95 PT which if reached, will make NASDAQ:KIN worth $56.75M more.
Analysts await Kindred Biosciences Inc (NASDAQ:KIN) to report earnings on November, 14. They expect $-0.36 earnings per share, 0.00% or $0.00 from last year’s $-0.36 per share. After $-0.25 actual earnings per share reported by Kindred Biosciences Inc for the previous quarter, Wall Street now forecasts 44.00% negative EPS growth.
According to Zacks Investment Research, “Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.”
Insitutional Activity: The institutional sentiment increased to 3.13 in 2016 Q2. Its up 2.48, from 0.65 in 2016Q1. The ratio improved, as 3 funds sold all Kindred Biosciences Inc shares owned while 5 reduced positions. 4 funds bought stakes while 21 increased positions. They now own 25.54 million shares or 107.22% more from 12.33 million shares in 2016Q1.
Jackson Park Cap Ltd Liability holds 77,000 shares or 0.37% of its portfolio. Norman Fields Gottscho Capital Mgmt Ltd Liability Company accumulated 13,900 shares or 0.03% of the stock. Blackrock Mngmt Limited has 0% invested in the company for 2,994 shares. Moreover, Deutsche Natl Bank Ag has 0% invested in Kindred Biosciences Inc (NASDAQ:KIN) for 36,638 shares. Blackrock Advsrs Limited Liability Com holds 0% or 26,171 shares in its portfolio. Connor Clark Lunn Investment Mgmt Limited holds 62,725 shares or 0% of its portfolio. Fmr Ltd Liability has 0% invested in the company for 219,950 shares. Wells Fargo And Mn reported 2,989 shares or 0% of all its holdings. Old West Inv Mgmt has 46,428 shares for 0.12% of their US portfolio. Bank & Trust Of Montreal Can accumulated 0% or 18 shares. The Ohio-based Osborn Rohs Williams & Donohoe has invested 0.04% in Kindred Biosciences Inc (NASDAQ:KIN). Ecor1 Capital Limited Liability has 1.43 million shares for 2% of their US portfolio. Moreover, Jpmorgan Chase has 0% invested in Kindred Biosciences Inc (NASDAQ:KIN) for 235,408 shares. Mufg Americas Corporation last reported 0% of its portfolio in the stock. Goldman Sachs Gp last reported 0% of its portfolio in the stock.
More notable recent Kindred Biosciences Inc (NASDAQ:KIN) news were published by: Prnewswire.com which released: “Kindred Biosciences to Present at 2016 Ladenburg Thalmann Healthcare Conference” on September 20, 2016, also Prnewswire.com with their article: “Kindred Biosciences to Participate in a BIO Animal Biotech Summit Panel” published on September 15, 2016, Quotes.Wsj.com published: “News Kindred Biosciences Inc.KIN” on December 07, 2013. More interesting news about Kindred Biosciences Inc (NASDAQ:KIN) were released by: Prnewswire.com and their article: “Kindred Biosciences Announces Positive Results from Pivotal Study of KIND-010 …” published on May 16, 2016 as well as Prnewswire.com‘s news article titled: “Kindred Biosciences Submits Zimeta (KIND-012) New Animal Drug Application …” with publication date: February 11, 2016.
KIN Company Profile
Kindred Biosciences, Inc., incorporated on September 25, 2012, is a development-stage biopharmaceutical company. The Firm is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Firm is developing product candidates for over 20 indications and focused on small molecule products, and canine and feline biologics products. The Company’s biologic product candidates are based on therapies and targets, for which products have been commercialized for humans. The Firm is developing antibodies that target canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company’s lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.